Amberstone Biosciences, Inc, based in Irvine, CA, is a pioneering biotech company that is transforming the landscape of immunotherapy. Their innovative technology, T-MATE, allows for the development of safe and effective immunotherapies by targeting tumors without damaging healthy tissues, eliminating the issues of dose toxicity that often interfere with drug efficacy. With a diverse library of therapeutic agents and a selectively activated approach, Amberstone Biosciences is able to develop transformative therapeutic strategies that were previously deemed impossible due to high toxicity.
Driven by their proprietary single-cell microfluidics platform technology, AmberFlow, the company isolates and engineers rare functional clones to discover pipeline therapeutics. This approach enables them to obtain valuable qualitative data much earlier in the discovery process, delivering on the promise of new modalities in immuno-oncology. With recent funding and the formation of a scientific advisory board, Amberstone Biosciences is at the forefront of pioneering breakthroughs in the field of immunotherapy.
Generated from the website